Zydus Lifesciences has entered into an exclusive agreement with Myriad Genetics to launch cancer-risk assessment diagnostic tests in India. The agreement involves the introduction of MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus, and Prolaris® Prostate Cancer Prognostic Test. This collaboration aims to provide personalized, evidence-based cancer care, enhancing risk assessment and treatment planning for patients across India. The announcement was made on December 19, 2025.
Strategic Collaboration for Cancer Diagnostics
Zydus Lifesciences has signed an agreement with Myriad Genetics to introduce advanced cancer diagnostic tests in India. The agreement, announced on December 19, 2025, focuses on bringing Myriad Genetics’ molecular diagnostic testing capabilities to the Indian market. These tests will aid in assessing cancer risk and guiding treatment decisions, marking a significant step towards precision medicine in India.
Key Diagnostic Tests
The agreement includes the following tests:
- MyRisk® Hereditary Cancer Test: This test helps people understand their cancer risk and take proactive steps to minimize that risk.
- MyChoice® HRD Plus: Used for patients with ovarian cancer, this test provides insights into disease progression and informs treatment strategies.
- Prolaris® Prostate Cancer Prognostic Test: This test is designed to assist patients with prostate cancer by improving the understanding of their disease.
Statements from Leadership
Dr. Sharvil P. Patel, Managing Director, Zydus, emphasized the importance of this agreement in expanding access to precision diagnostic tests for cancer treatment in India. He highlighted that the tests will equip doctors with actionable insights for personalized treatment plans. Brian Donnelly, Chief Commercial Officer for Myriad Genetics, mentioned that these tests aim to empower clinicians with information to assess risk, understand tumors, and guide personalized care.
Advancing Cancer Care in India
The collaboration between Zydus Lifesciences and Myriad Genetics aims to strengthen clinician education and diagnostic infrastructure, ensuring patients benefit from early and accurate risk assessment. This effort promotes personalized, evidence-based cancer care, offering clarity and support throughout a patient’s journey.
Source: BSE
